EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR T cell engineering approaches to minimise toxicities

Elizabeth Hogben, Anna Schurich, Charlotte Graham

Experimental Biology and Medicine · 15.04.2026 · 251

DOI: 10.3389/ebm.2026.11021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 15.04.2026. Verfasst von Elizabeth Hogben und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: T-Lymphocytes, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For the treatment of many forms of cancer, cell- and gene-based therapies are showing promise in both pre-clinical data and clinical trials. In particular, CAR T cell therapies, of which there are now 7 FDA-approved products, have shown ground-breaking results in haematological cancers such as multiple myeloma and B cell malignancies. Recent research is also attempting to develop effective CAR T cell therapies for solid tumours, with varying success. One of the key challenges faced by CAR T cell therapy is balancing strong cytotoxic activity for an effective treatment with preventing severe and potentially lethal toxicities, such as Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome. This mini review discusses some of the potential solutions that scientists have devised to overcome toxicities and improve existing CAR T cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesReceptors, Chimeric AntigenImmunotherapy, AdoptiveCytokine Release SyndromeNeoplasmsHumansAnimalsCell Engineering

Stichwörter der Autor:innen

CAR T cellICANScytokine release syndrome (CRS)non-ICANS neurotoxicitysafetytoxicity

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Haematology, King's College London, London, United Kingdom.
  • Department of Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom.

Förderung

  • Medical Research Council

Zitieren

APA

Hogben, E., Schurich, A., & Graham, C. (2026). CAR T cell engineering approaches to minimise toxicities. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.11021

Vancouver

Hogben E, Schurich A, Graham C. CAR T cell engineering approaches to minimise toxicities. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.11021

BibTeX
@article{Hogben2026,
  author = {Hogben, Elizabeth and Schurich, Anna and Graham, Charlotte},
  title = {CAR T cell engineering approaches to minimise toxicities},
  journal = {Experimental Biology and Medicine},
  year = {2026},
  volume = {251},
  doi = {10.3389/ebm.2026.11021}
}
Kostenlos starten →